Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lyme disease
CRO
Pfizer, Valneva overcome CRO Lyme disease recruitment problems
Pfizer and Valneva have completed recruitment for a phase 3 trial of the Lyme disease vaccine VLA15 after work was halted earlier this year.
Joseph Keenan
Dec 5, 2023 3:20pm
Pfizer links Lyme booster to phase 2 pediatric antibody response
Sep 7, 2023 7:30am
Pfizer cuts enrollment for Lyme disease trial after CRO debacle
Aug 22, 2023 1:00pm
Pfizer pulls 50% of people from phase 3 trial for GCP violations
Feb 17, 2023 6:00am
Pfizer-Valneva's Lyme vaccine triggers 6-month antibody response
Dec 1, 2022 8:00am
Pfizer triggers surge in Valneva's stock with €91M investment
Jun 21, 2022 9:50am